InvestorsHub Logo
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

Re: biopearl post# 17777

Sunday, 10/08/2017 2:22:07 PM

Sunday, October 08, 2017 2:22:07 PM

Post# of 20689

After copax…do you see that next value-creating event as market approval for the Orencia copy?

No, M834 (Orencia FoB) is just finishing up phase-1, while M923 (Humira FoB) is nearly ready for submission of the 351(k) BLA. So, M923 is 1-2 years ahead of M834.

Moreover, there are various milestones in MNTA’s autoimmune programs that will precede FDA approval of M834. Please see the immediately following news flow post for details. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”